Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Inhibition of neuronal FLT3 receptor tyrosine kinase alleviates peripheral neuropathic pain in mice.

Rivat C, Sar C, Mechaly I, Leyris JP, Diouloufet L, Sonrier C, Philipson Y, Lucas O, Mallié S, Jouvenel A, Tassou A, Haton H, Venteo S, Pin JP, Trinquet E, Charrier-Savournin F, Mezghrani A, Joly W, Mion J, Schmitt M, Pattyn A, Marmigère F, Sokoloff P, Carroll P, Rognan D, Valmier J.

Nat Commun. 2018 Mar 12;9(1):1042. doi: 10.1038/s41467-018-03496-2.

2.

Vascular plant biodiversity of the lower Coppermine River valley and vicinity (Nunavut, Canada): an annotated checklist of an Arctic flora.

Saarela JM, Sokoloff PC, Bull RD.

PeerJ. 2017 Jan 31;5:e2835. doi: 10.7717/peerj.2835. eCollection 2017.

3.

The dopamine D3 receptor, a quarter century later.

Sokoloff P, Le Foll B.

Eur J Neurosci. 2017 Jan;45(1):2-19. doi: 10.1111/ejn.13390. Epub 2016 Oct 3. Review.

PMID:
27600596
4.

The "Martian" flora: new collections of vascular plants, lichens, fungi, algae, and cyanobacteria from the Mars Desert Research Station, Utah.

Sokoloff PC, Freebury CE, Hamilton PB, Saarela JM.

Biodivers Data J. 2016 Jun 9;(4):e8176. doi: 10.3897/BDJ.4.e8176. eCollection 2016.

5.

Developmental and adult expression patterns of the G-protein-coupled receptor GPR88 in the rat: Establishment of a dual nuclear-cytoplasmic localization.

Massart R, Mignon V, Stanic J, Munoz-Tello P, Becker JA, Kieffer BL, Darmon M, Sokoloff P, Diaz J.

J Comp Neurol. 2016 Oct 1;524(14):2776-802. doi: 10.1002/cne.23991. Epub 2016 Mar 16.

PMID:
26918661
6.

A GIPC1-Palmitate Switch Modulates Dopamine Drd3 Receptor Trafficking and Signaling.

Arango-Lievano M, Sensoy O, Borie A, Corbani M, Guillon G, Sokoloff P, Weinstein H, Jeanneteau F.

Mol Cell Biol. 2016 Jan 19;36(6):1019-31. doi: 10.1128/MCB.00916-15.

7.

New vascular plant records for the Canadian Arctic Archipelago.

Gillespie LJ, Saarela JM, Sokoloff PC, Bull RD.

PhytoKeys. 2015 Jun 25;(52):23-79. doi: 10.3897/phytokeys.52.8721. eCollection 2015.

8.

Dopamine D3 receptor ligands for drug addiction treatment: update on recent findings.

Le Foll B, Collo G, Rabiner EA, Boileau I, Merlo Pich E, Sokoloff P.

Prog Brain Res. 2014;211:255-75. doi: 10.1016/B978-0-444-63425-2.00011-8. Review.

PMID:
24968784
9.

Mass spectrometric detection and characterization of atypical membrane-bound zinc-sensitive phosphatases modulating GABAA receptors.

SidAhmed-Mezi M, Kurcewicz I, Rose C, Louvel J, Sokoloff P, Pumain R, Laschet JJ.

PLoS One. 2014 Jun 26;9(6):e100612. doi: 10.1371/journal.pone.0100612. eCollection 2014.

10.

DNA barcoding the Canadian Arctic flora: core plastid barcodes (rbcL + matK) for 490 vascular plant species.

Saarela JM, Sokoloff PC, Gillespie LJ, Consaul LL, Bull RD.

PLoS One. 2013 Oct 22;8(10):e77982. doi: 10.1371/journal.pone.0077982. eCollection 2013.

11.

Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia.

Sokoloff P, Leriche L, Diaz J, Louvel J, Pumain R.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Feb;386(2):107-24. doi: 10.1007/s00210-012-0797-0. Epub 2012 Sep 22.

12.

New therapeutic targets to develop molecules active in drug-resistant epilepsies.

SidAhmed-Mezi M, Pumain R, Louvel J, Sokoloff P, Laschet J.

Epilepsia. 2010 Jul;51 Suppl 3:43-7. doi: 10.1111/j.1528-1167.2010.02608.x.

13.
14.

Cellular BRET assay suggests a conformational rearrangement of preformed TrkB/Shc complexes following BDNF-dependent activation.

De Vries L, Finana F, Cachoux F, Vacher B, Sokoloff P, Cussac D.

Cell Signal. 2010 Jan;22(1):158-65. doi: 10.1016/j.cellsig.2009.09.027. Epub 2009 Sep 22.

PMID:
19781635
15.

Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies.

Blin O, Audebert C, Pitel S, Kaladjian A, Casse-Perrot C, Zaim M, Micallef J, Tisne-Versailles J, Sokoloff P, Chopin P, Marien M.

Psychopharmacology (Berl). 2009 Dec;207(2):201-12. doi: 10.1007/s00213-009-1648-7. Epub 2009 Sep 16.

PMID:
19756528
16.

Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents.

Massart R, Guilloux JP, Mignon V, Sokoloff P, Diaz J.

Eur J Neurosci. 2009 Aug;30(3):397-414. doi: 10.1111/j.1460-9568.2009.06842.x. Epub 2009 Jul 28.

PMID:
19656174
17.

Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid.

Alvarez-Fischer D, Guerreiro S, Hunot S, Saurini F, Marien M, Sokoloff P, Hirsch EC, Hartmann A, Michel PP.

J Neurochem. 2008 Nov;107(3):701-11. doi: 10.1111/j.1471-4159.2008.05651.x. Epub 2008 Sep 16.

18.

Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels.

Guerreiro S, Toulorge D, Hirsch E, Marien M, Sokoloff P, Michel PP.

Mol Pharmacol. 2008 Oct;74(4):980-9. doi: 10.1124/mol.108.048207. Epub 2008 Jul 11.

20.

Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype.

Guiard BP, David DJ, Deltheil T, Chenu F, Le Maître E, Renoir T, Leroux-Nicollet I, Sokoloff P, Lanfumey L, Hamon M, Andrews AM, Hen R, Gardier AM.

Int J Neuropsychopharmacol. 2008 Feb;11(1):79-92. Epub 2007 Jun 11.

PMID:
17559709
21.

N-(4-(4-(2-Halogenophenyl)piperazin-1-yl)butyl) substituted cinnamoyl amide derivatives as dopamine D2 and D3 receptor ligands.

Saur O, Hackling AE, Perachon S, Schwartz JC, Sokoloff P, Stark H.

Arch Pharm (Weinheim). 2007 Apr;340(4):178-84.

PMID:
17405129
22.

Dopamine D3 receptor ligands for the treatment of tobacco dependence.

Le Foll B, Goldberg SR, Sokoloff P.

Expert Opin Investig Drugs. 2007 Jan;16(1):45-57. Review.

PMID:
17155853
23.

A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor.

Jeanneteau F, Funalot B, Jankovic J, Deng H, Lagarde JP, Lucotte G, Sokoloff P.

Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10753-8. Epub 2006 Jun 29.

24.

Linkage with the Ser9Gly DRD3 polymorphism in essential tremor families.

Lucotte G, Lagarde JP, Funalot B, Sokoloff P.

Clin Genet. 2006 May;69(5):437-40. No abstract available.

PMID:
16650084
25.

The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.

Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C.

CNS Neurol Disord Drug Targets. 2006 Feb;5(1):25-43. Review.

PMID:
16613552
26.

Practicing what preach. A Kansas City organization aligns day-to-day practice with espoused beliefs.

Sokoloff P.

Health Prog. 2006 Jan-Feb;87(1):73-8. No abstract available.

PMID:
16519288
27.

The dopamine D3 receptor and drug dependence: effects on reward or beyond?

Le Foll B, Goldberg SR, Sokoloff P.

Neuropharmacology. 2005 Sep;49(4):525-41. Review.

PMID:
15963538
28.

Focus on clozapine: a new explanation for its atypical character.

Sokoloff P.

Int J Neuropsychopharmacol. 2005 Sep;8(3):311-3. Epub 2005 May 13. No abstract available.

PMID:
15896266
29.

Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.

Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, Håkansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E.

Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S25-9. Review.

PMID:
15885624
30.

A single cocaine exposure increases BDNF and D3 receptor expression: implications for drug-conditioning.

Le Foll B, Diaz J, Sokoloff P.

Neuroreport. 2005 Feb 8;16(2):175-8.

PMID:
15671872
31.

Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice.

Le Foll B, Diaz J, Sokoloff P.

Life Sci. 2005 Jan 28;76(11):1281-96. Epub 2004 Dec 25.

PMID:
15642598
33.

Subapical localization of the dopamine D3 receptor in proximal tubules of the rat kidney.

Nürnberger A, Räbiger M, Mack A, Diaz J, Sokoloff P, Mühlbauer B, Luippold G.

J Histochem Cytochem. 2004 Dec;52(12):1647-55.

PMID:
15557219
34.

Role of DRD3 in morphine-induced conditioned place preference using drd3-knockout mice.

Francès H, Le Foll B, Diaz J, Smirnova M, Sokoloff P.

Neuroreport. 2004 Oct 5;15(14):2245-9.

PMID:
15371743
35.

GIPC recruits GAIP (RGS19) to attenuate dopamine D2 receptor signaling.

Jeanneteau F, Guillin O, Diaz J, Griffon N, Sokoloff P.

Mol Biol Cell. 2004 Nov;15(11):4926-37. Epub 2004 Sep 8.

36.

Glyceraldehyde-3-phosphate dehydrogenase is a GABAA receptor kinase linking glycolysis to neuronal inhibition.

Laschet JJ, Minier F, Kurcewicz I, Bureau MH, Trottier S, Jeanneteau F, Griffon N, Samyn B, Van Beeumen J, Louvel J, Sokoloff P, Pumain R.

J Neurosci. 2004 Sep 1;24(35):7614-22.

37.
38.

Development of novel 1,2,3,4-tetrahydroisoquinoline derivatives and closely related compounds as potent and selective dopamine D3 receptor ligands.

Mach UR, Hackling AE, Perachon S, Ferry S, Wermuth CG, Schwartz JC, Sokoloff P, Stark H.

Chembiochem. 2004 Apr 2;5(4):508-18.

PMID:
15185375
39.

Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor.

Leriche L, Diaz J, Sokoloff P.

Neurotox Res. 2004;6(1):63-71. Review.

PMID:
15184107
40.

Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference.

Francès H, Smirnova M, Leriche L, Sokoloff P.

Psychopharmacology (Berl). 2004 Sep;175(2):127-33. Epub 2004 Apr 17.

PMID:
15095031
41.

Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway.

Guillin O, Griffon N, Diaz J, Le Foll B, Bezard E, Gross C, Lammers C, Stark H, Carroll P, Schwartz JC, Sokoloff P.

Int Rev Neurobiol. 2004;59:425-44. Review. No abstract available.

PMID:
15006497
42.

The dopamine D3 receptor and drug addiction.

Sokoloff P, Le Foll B, Perachon S, Bordet R, Ridray S, Schwartz JC.

Neurotox Res. 2001 Oct;3(5):433-41.

PMID:
14715457
43.

Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease.

Guillin O, Griffon N, Bezard E, Leriche L, Diaz J, Gross C, Sokoloff P.

Eur J Pharmacol. 2003 Nov 7;480(1-3):89-95. Review.

PMID:
14623353
44.

Interactions of GIPC with dopamine D2, D3 but not D4 receptors define a novel mode of regulation of G protein-coupled receptors.

Jeanneteau F, Diaz J, Sokoloff P, Griffon N.

Mol Biol Cell. 2004 Feb;15(2):696-705. Epub 2003 Nov 14.

45.

CLIC6, a member of the intracellular chloride channel family, interacts with dopamine D(2)-like receptors.

Griffon N, Jeanneteau F, Prieur F, Diaz J, Sokoloff P.

Brain Res Mol Brain Res. 2003 Sep 10;117(1):47-57.

PMID:
14499480
46.

N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands.

Hackling A, Ghosh R, Perachon S, Mann A, Höltje HD, Wermuth CG, Schwartz JC, Sippl W, Sokoloff P, Stark H.

J Med Chem. 2003 Aug 28;46(18):3883-99.

PMID:
12930150
47.

The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade.

Leriche L, Schwartz JC, Sokoloff P.

Neuropharmacology. 2003 Aug;45(2):174-81.

PMID:
12842123
48.

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.

Bézard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, Sokoloff P.

Nat Med. 2003 Jun;9(6):762-7. Epub 2003 May 12.

PMID:
12740572
49.

Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental psychiatric disorders.

Sokoloff P, Guillin O, Diaz J, Carroll P, Griffon N.

Neurotox Res. 2002 Nov-Dec;4(7-8):671-678.

PMID:
12709305
50.

Disruption of nicotine conditioning by dopamine D(3) receptor ligands.

Le Foll B, Schwartz JC, Sokoloff P.

Mol Psychiatry. 2003 Feb;8(2):225-30.

PMID:
12610655

Supplemental Content

Loading ...
Support Center